Valeant Pharmaceuticals Intl Inc.: Next Stop $10?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) remains a risky bet.

The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) continues to struggle, and investors are wondering where the stock might finally bottom out.

Let’s take a look at the current situation to see if more pain could be on the way.

Downbeat results

Valeant wasn’t expected to deliver a great Q3, but the company’s results came in worse than analysts expected.

Adjusted earnings were US$1.55 per share compared to the US$1.75 per share the market anticipated. Slowing sales in the dermatology business were partly to blame, as was competitive pressure in the generic drug business.

Investors were not overly impressed with the results, but the negative guidance really upset the market.

Why?

Valeant said the fourth quarter was going to be challenging, and difficulties are expected to continue into 2017 as patent expirations could offset any improvements that arrive as a result of the ongoing restructuring efforts.

Debt load

Valeant finished Q3 with long-term debt of US$30.4 billion. That’s a lot for a company that only has a market capitalization of about US$5.2 billion.

Management is determined to reduce the obligations, and assets sales are going to be a part of that process.

At the start of November, the stock surged on reports the company was close to a US$10 billion deal to sell Salix, its stomach-drugs group. Four weeks later, the stock tanked again on news negotiations with a Japanese buyer broke down.

The latest on the story is that Valeant plans to keep the division. Apparently, the buyer was looking for a fire-sale deal.

Valeant paid close to US$11 billion for Salix last year, so the US$10 billion price tag floating around the rumour mill was already a discount.

Should you buy?

Valeant remains a risky bet.

The company is caught up in legal battles, and the entire drug sector is under government scrutiny for its pricing policies.

Fans of the stock say the underlying business has great potential, and one report even suggests there could be 100% upside from the current price. At this point, however, further bad news or a broad-based pullback in equity markets could easily send the stock much lower.

In fact, a dip to $10 wouldn’t be a surprise.

If you have a contrarian investing style and a strong stomach for volatility, Valeant might be worth a shot on further weakness, but I would keep the position small.

Fool contributor Andrew Walker has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »